Research programme: neurological disorder therapeutics- biOasis/Astellas

Drug Profile

Research programme: neurological disorder therapeutics- biOasis/Astellas

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator Astellas Pharma US
  • Developer Astellas Pharma US; biOasis Technologies
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurological disorders

Most Recent Events

  • 21 Apr 2016 Early research in Neurological disorders in USA (unspecified route)
  • 21 Apr 2016 biOasis and Astellas enter into a licensing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top